Repligen (RGEN) Tops Q3 EPS by 14c, Raises FY Guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $165.66 -1.31%
Revenue Growth %: -17.9%
Financial Fact:
Selling, general and administrative: 7.13M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: -17.9%
Financial Fact:
Selling, general and administrative: 7.13M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.78, $0.14 better than the analyst estimate of $0.64. Revenue for the quarter came in at $178.2 million versus the consensus estimate of $163.97 million.
GUIDANCE:
Repligen sees FY2021 EPS of $2.86-$2.91, versus the consensus of $2.68. Repligen sees FY2021 revenue of $655-665 million, versus the consensus of $640.6 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- MidWestOne Financial Group, Inc. (MOFG) Misses Q1 EPS by 15c
- PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
